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Abbreviations 
    LED: Light Emitting Diode; DUV-LED: Deep Ultraviolet Light Emitting Diode; Gcmaf: Gc protein-derived 
Macrophage-Activating Factor; 5-ALA: 5-Aminolevulinic Acid; PPIX: Protoporphyrin IX; SARS-Cov-2: Severe Acute 
Respiratory Syndrome Coronavirus-2 
 
    Across the world, the COVID-19 pandemic has been 
a medical, social, human, and economic crucial 
problem. A variety of actual management for daily life 
and novel research for treatments have been continued 
[1]. As a matter of fact, the excess mortality of COVID-
19 in Japan has been  the  lowest  with  minus 15000 in 
the world [2-4]. Among them, several new trials have 
been found in Japan, which are introduced and 
described in this article. 
 
    Formerly, a historical invention of white InGaN 
based   light  emitting  diodes  (LEDs)   and   blue  laser 
 
Abstract 
    Several trials for the COVID-19 pandemic are found. Prof. Shunji Nakamura, Tokushima University was 
awarded the 2014 Nobel prize in Physics for light-emitting diodes (LEDs). Deep ultraviolet LED (DUV-LED) 
causes SARS-CoV-2 inactivation as 99.9% by 265 nm. Gc protein-derived macrophage-activating factor 
(GcMAF)-based immunotherapy has a wider application for serious infection, chronic fatigue syndrome, and 
cancers. Covid center in Naples submitted a phase II report concerning GcMAF and COVID-19 in Feb 2021.  5-
aminolevulinic acid (5-ALA) and its metabolite protoporphyrin IX (PpIX) show anti-inflammatory and 
antiviral effects for Zika, Dengue, influenza A viruses, and SARS-CoV-2. These results hopefully contribute to 
the research development for COVID-19. 
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diodes (LDs) was achieved by Prof. Shunji Nakamura, 
Tokushima University. He was awarded the 2014 
Nobel prize in Physics [5]. Using this deep ultraviolet 
light-emitting diode (DUV-LED), quantitative 
evaluation of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) inactivation was reported 
as 99.9% in 2021 [6]. For the achievement of this 
level, total doses of 1.8 mJ/cm
2
 for 265 nm, 3.0 mJ/cm
2
 
for 280 nm, and 23 mJ/cm
2
 for 300 nm are required. 
These data could provide the quantitative antiviral 
clinical efficacy by DUV irradiation on SARS-COV-2, 
which serves the fundamental knowledge of 
inactivation methods for SARS-COV-2. This project 
was supported by Tokushima Prefectural Government 
and Tokushima University. According to the data 
mentioned above, some experiments were conducted 
using LEDs systems by changing the condition [7]. As a 
result, a wavelength of 260 nm was most effective for 
the inactivation of coronavirus particles. This research 
will be expected to develop for broad application 
worldwide. 
 
    Another international research has been found. 
Clinical research for Gc protein-derived macrophage-
activating factor (GcMAF) has been continued in 
Tokushima University for years [8]. GcMAF has a 
variety of functions as an immune modulator, 
including macrophage activation, anti-tumor activity, 
and anti-angiogenic activity. Consequently, GcMAF-
based immunotherapy shows a wider application for 
serious infection, chronic fatigue syndrome, multiple 
sclerosis, and several cancers [9]. GcMAF has the 
possibility of the role for suppressing the severity of 
COVID-19-induced immune responses [10]. Covid 
center in Naples, Italy summarized the phase II report 
concerning GcMAF and COVID-19 pneumonia with 104 
references and 63 pages in Feb 2021 [11]. Further 
development for the interaction of GcMAF and COVID-
19 will be expected.  
 
    The third topic is 5-aminolevulinic acid (5-ALA). The 
research group of Tokushima University formerly 
reported the involvement of 5-ALA, which is the 
precursor of protoporphyrin IX (PpIX) for the possible 
sonosensitizers for sonodynamic treatment of cancers 
[12]. 5-ALA is a synthesized amino acid and has      
been  applied  for  various  purposes such as anticancer 
 
 
therapy or as a dietary supplement. Recently, it has 
been showed potently inhibition of infection of SARS-
CoV-2 in cell culture. The detailed research has been 
continued at Nagasaki University in Japan [13]. Its 
antiviral efficacy was detected in both human and non-
human cells with no significant cytotoxicity.  
 
    5-ALA is one of the natural amino acids and exists in 
plants, bacteria, fungi, and animals. The conjugation of 
8 molecules of 5-ALA bring the production of PPIX, 
which can generate heme with the ferrous ion 
insertion. Since 5-ALA strengthens the aerobic energy 
metabolism, it is applied for improved metabolism in 
such as diabetes mellitus [14]. Its application was 
broadened for infections such as malaria [15]. 
Furthermore, PPIX was known to show antiviral 
efficacy for various viruses including Zika virus, 
Dengue virus, influenza A virus, and also SARS-CoV-2 
[16]. 
 
    It has been reported that exogenously supplied 5-
ALA affects the host through various mechanisms [17]. 
Metabolites of 5-ALA such as PPIX and hem seem to 
affect viral infection existing inside the host cells. A 
recent report demonstrated that a G-quadruplex (G4)-
binding compound could inhibit SARS-CoV-2 
replication [18]. G4s show tetra-helical structures 
made of guanine-rich regions of DNA or RNA, which 
can regulate gene expression, genome stability, and 
adequate control of protein quality [19]. G4 structures 
have been observed in the genome of many kinds of 
viruses such as coronaviruses and can regulate viral 
replication cycles. As to recent studies, G4 structures of 
the SARS-CoV-2 RNA genome and its interaction with 
the binding proteins would become possibly antiviral 
targets to attach COVID-19 [18,20]. In addition, heme 
is the metabolites of 5-ALA and a ligand of G4 
structures [21]. Consequently, exogenous 5-ALA 
administration leads to increased production of PPIX 
and heme inside the host cells, which may interfere 
with the interaction of G4 structures or virus genome 
leading to inhibition of SARS-CoV-2 infection. 
 
    5-ALA is synthesized in most plants and animals, 
and then we always consume it within our daily foods 
[22]. Then, it is safely provided to humans as a 
supplement or medicine for a wider population
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including mild cases of patients with COVID-19 [23]. 
Moreover, 5-ALA shows anti-inflammatory efficacy in 
humans, and then it is possible to provide rather 
severe cases for the combined therapy for anti-
inflammation and antiviral activity [22]. Concerning 
the research of 5-ALA and COVID-19, experiments 
using swine have been found [24,25]. Consequently, 
further studies of antiviral function by animal 
experiments and mechanistic research will be 
expected. 
 
    As mentioned above, several recent topics were 
introduced and discussed in this article. They include i) 
SARS-CoV-2 inactivation was 99.9% by DUV-LED, ii) 
GcMAF would be effective as phase II report from Italy, 
iii) 5-ALA would be applied for COVID-19. The 
information will be hopefully prevalent across the 
world rapidly, leading to the health and happiness      
of all people with the development of research of 
COVID-19. 
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